Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)

id: 361532
Source ↗ · id

opportunityNumber: RFA-CA-26-010
Source ↗ · opportunityNumber

opportunityTitle: Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
Source ↗ · opportunityTitle

revision: 0
Source ↗ · revision

agencyDetails: {"code":"NIH","seed":"HHS-NIH11","agencyName":"National Institutes of Health","agencyCode":"HHS-NIH11","topAgencyCode":"HHS"}
Source ↗ · agencyDetails

owningAgencyCode: HHS-NIH11
Source ↗ · owningAgencyCode

cfdas: [{"id":432270,"opportunityId":361532,"cfdaNumber":"93.393","programTitle":"Cancer Cause and Prevention Research"},{"id":432271,"opportunityId":361532,"cfdaNumber":"93.394","programTitle":"Cancer Detection and Diagnosis Research"},{"id":432269,"opportunityId":361532,"cfdaNumber":"93.395","programTitle":"Cancer Treatment Research"}]
Source ↗ · cfdas

forecastDesc: <p>The goal of this RFA is to continue to support canine cancer immunotherapy clinical trials as indicators of safe and effective cancer treatments in humans. Pet dog patients develop cancer spontaneously and the courses of disease and treatment responses are similar to those in humans. Canine clinical trial results are translatable to humans. The assessment of responses to immunotherapy in immune-intact animals with existing cancers, such as pet dog patients, is the only way to preclinically take into account all facets of the immune response to cancer and to therapies. Ethically, pet dogs can benefit from the clinical trials by receiving cutting-edge therapies supported by the NIH, while providing important data informative to human disease. The network supported by this U01 RFA will consist of five U01 awards. One U01 will serve as a multifunctional Network Coordinating Center that will not only facilitate coordination across the Canine Cancer Immunotherapy Network (K9CIN) but will also perform limited research to support the network. Four U01 recipients will conduct canine clinical trials using immunotherapeutic agents alone or in combination with other treatment modalities.</p><p>Through this reissue Notice of Funding Opportunity, the National Cancer Institute intends to continue to support canine immunotherapeutic development as the field continues to grow, in part because of NIH funding. In the last five years, canine immunotherapeutics such as immune checkpoint inhibitors have become available as have canine analytics, development of which were partially supported by NCI. The goal is to maintain the momentum for further development of canine analytics and therapeutics and the ability to evaluate novel and repurposed drugs, treatment combinations, and treatment dosing and sequencing in pet dogs in a timely fashion. This NOFO consolidates the prior U01 (RFA-CA-21-050) and U24 (RFA-CA-21-051) funding opportunities to streamline the application process for continued support to K9CIN. Applicants have the option of submitting either for the Network Coordinating Center with limited research focus or for conducting canine cancer immunotherapy clinical trials and correlative studies. These important canine cancer-related activities will provide a valuable opportunity for NIH support to benefit humans and dogs, at both ends of the leash.</p>
Source ↗ · forecastDesc

applicantTypes: [{"id":"05","description":"Independent school districts"},{"id":"13","description":"Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"01","description":"County governments"},{"id":"08","description":"Public housing authorities/Indian housing authorities"},{"id":"23","description":"Small businesses"},{"id":"12","description":"Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"04","description":"Special district governments"},{"id":"00","description":"State governments"},{"id":"07","description":"Native American tribal governments (Federally recognized)"},{"id":"22","description":"For profit organizations other than small businesses"},{"id":"25","description":"Others (see text field entitled \"Additional Information on Eligibility\" for clarification)"},{"id":"06","description":"Public and State controlled institutions of higher education"},{"id":"11","description":"Native American tribal organizations (other than Federally recognized tribal governments)"},{"id":"02","description":"City or township governments"},{"id":"20","description":"Private institutions of higher education"}]
Source ↗ · applicantTypes

applicantEligibilityDesc: Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Source ↗ · applicantEligibilityDesc

fundingInstruments: [{"id":"CA","description":"Cooperative Agreement"}]
Source ↗ · fundingInstruments

fundingActivityCategories: [{"id":"HL","description":"Health"}]
Source ↗ · fundingActivityCategories

costSharing: false
Source ↗ · costSharing

lastUpdatedDate: Mar 18, 2026 10:21:49 AM EDT
Source ↗ · lastUpdatedDate

status: forecasted
Source ↗ · oppHits[id=361532].oppStatus